Towards Personalized Medicine By The Early Use Of Patient Data

Towards Personalized Medicine By The Early Use Of Patient Data

OPINION Traditional approaches to clinical drug development have created a critical gap between preclinical research and patient applications. Only the drugs that pass big clinical trials reach to the clinic, and a potentially heterogeneous group of patients end up...
Let’s reconsider your research – InnoSer contract breeding services

Let’s reconsider your research – InnoSer contract breeding services

COVID-19 restrictions brought extra challenges to breeding and maintaining colonies within academic facilities. If you are looking for a service provider resilient to today’s vulnerable environment, InnoSer is here to support you. Let’s put your research back on track...
PDX/O oncology platform developments at InnoSer

PDX/O oncology platform developments at InnoSer

Despite the challenging times for the life sciences sector during coronavirus restrictions, we’ve been fortunate enough and well prepared to continue with the development of our PDX/O platform for oncology research. On a weekly basis we receive patient tumor samples...
Taking Precautions Against Coronavirus

Taking Precautions Against Coronavirus

Following the most recent governmental advice and regulations, we have decided to take preventative measures against the fast spread of COVID-19. The health and interests of our customers, employees and other stakeholders are our top priority. In order to minimize the...
InnoSer and OrganoTherapeutics to Offer Midbrain Organoids

InnoSer and OrganoTherapeutics to Offer Midbrain Organoids

InnoSer is joining forces with OrganoTherapeutics to make midbrain organoids available for screening and development of pharmaceutical compounds. This partnership will enable providing midbrain organoids commercially as a platform for Parkinson’s disease research. CEO...